Azora Therapeutics Inc. (AZR:NASDAQ) closed at $4.09 on November 13, 2026, up 9.36% on the day. The stock trades 50.4% below its 52-week high of $8.25 and 212.2% above its 52-week low of $1.31. Over the past year, it gained 155.6%. Azora Therapeutics Inc. is part of the Health Care sector.
In 135 trading sessions since May 5, 2026, AZR closed higher on 72 days (53%). Its best day was June 11, 2026 (+37.96%) and its worst was October 30, 2026 (-21.93%). The stock moved 10% or more in a single session 16 times.
Azora Therapeutics Inc. is a biopharmaceutical company focused on developing treatments for serious inflammatory diseases. The company was spun out of Stanford University after being incubated in the translational medicine SPARK program. Azora owns the worldwide royalty-free rights to its technology, which is based on the development of potential best-in-class oral agonists of the aryl hydrocarbon receptor. Azora's lead program is AT177, a proprietary colon-targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis.
Find more stocks like AZR with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.